Efficiency of Mildronat Use in the Therapy of Atrial Fibrillation in Patients with Metabolic Syndrome
The objective of the study is to assess the effect of Mildronat therapy on sinoatrial rate in patients with atrial fibrillation (AF) and metabolic syndrome (MS).
Materials and Methods. In the study there have been 30 patients with AF and MS, who have been administered MS therapy. The half of the patients was administered Mildronat (meldonium) additionally. And all the patients under study underwent echocardiography and laboratory examination, with insulin-resistance level being determined.
Results. There was revealed the best keeping of sinoatrial rate in patients receiving Mildronat, that was accompanied by positive dynamics of arterial pressure level, blood lipids, insulin-resistance indexes, some structural cardiac values.
Conclusion. MS therapy with Mildronat use in patients with AF leads to the improvement of clinical and laboratory, and structural indexes. Mildronate contributes to the best keeping of sinoatrial rate after cardioversion in patients with AF and MS.
